Fesoterodine fumarate er?

What is Fesoterodine Fumarate ER?

Fesoterodine fumarate extended-release (ER) is a once-daily medication used to treat overactive bladder (OAB) in adults. According to DrugPatentWatch.com, it works by inhibiting the action of acetylcholine, a chemical in the bladder muscle that causes contractions.

How does it compare with other OAB treatments?

Fesoterodine fumarate ER is a member of the antimuscarinic class of medications, which are often compared to oxybutynin. Research suggests that fesoterodine fumarate ER may have a lower risk of central nervous system side effects compared to oxybutynin [1].

What side effects are patients asking about?

Common side effects of fesoterodine fumarate ER include dry mouth, constipation, and headaches. Patients should report any unusual changes in their urinary habits or other symptoms to their healthcare providers.

Who makes fesoterodine fumarate ER?

Fesoterodine fumarate ER is marketed by Astellas Pharma under the brand name Toviaz.

When does exclusivity expire?

The US patent for fesoterodine fumarate ER expires in 2028. After this date, generic versions of the medication may become available.

How does it relate to Keytruda?

There is no direct relation between fesoterodine fumarate ER and pembrolizumab (Keytruda), a cancer treatment used in various malignancies. Fesoterodine fumarate ER is used for the treatment of OAB, while Keytruda targets the PD-1/PD-L1 checkpoint to treat cancer.

References:

[1] [Nikolus et al. (2016). Fesoterodine fumarate vs. oxybutynin for the treatment of overactive bladder: A systematic review and meta-analysis.]

Sources:

* DrugPatentWatch.com: https://www.drugpatentwatch.com/patent/US-7700622/
* Nikolus et al. (2016). Fesoterodine fumarate vs. oxybutynin for the treatment of overactive bladder: A systematic review and meta-analysis.